×
About 4,040 results

ALLMedicine™ Crohn Disease Center

Research & Reviews  1,343 results

Vedolizumab-Induced Acne Fulminans: An Uncommon and Severe Adverse Effect
https://www.mdedge.com/dermatology/article/258465/acne/vedolizumab-induced-acne-fulminans-uncommon-and-severe-adverse
Kaitlin Blankenship, MD, Laura Burns, MD et. al.

Oct 6th, 2022 - To the Editor: Vedolizumab is an innovative monoclonal antibody targeted against the α4β7 integrin that is approved for treatment of moderate to severe ulcerative colitis and Crohn disease refractory to standard treatment. 1 Vedolizumab is thought.

In active Crohn disease, risankizumab increased clinical remission and endoscopic respo...
https://doi.org/10.7326/J22-0080
Annals of Internal Medicine; Oliver D, Talley NJ

Oct 4th, 2022 - D'Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015-30. 35644154.

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for...
https://doi.org/10.1001/jamanetworkopen.2022.34200
JAMA Network Open; Singh S, Iversen AT et. al.

Oct 1st, 2022 - Observational comparative effectiveness studies can inform the positioning of biologic therapies for older patients with inflammatory bowel disease (IBD) who are underrepresented in clinical trials. To compare the effectiveness and safety of vedol...

Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease
https://clinicaltrials.gov/ct2/show/NCT03712826

Sep 30th, 2022 - Crohn disease is an inflammatory chronic disease of the bowel the complex physiopathology of which brings in immunological, genetic and environmental factors. At present, the appeal to biotherapics anti-TNFa (infliximab and adalimumab) or anti-IL-...

The Correlation between Endotoxin, D-Lactate, and Diamine Oxidase with Endoscopic Activ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507744
Disease Markers; Zhang Q, Gao X et. al.

Sep 27th, 2022 - A total of 149 eligible IBD patients including 82 Crohn disease (CD) and 67 Ulcerative colitis (UC) who had received both endoscopic examination and intestinal barrier function detection in our hospital were enrolled in this study. Endoscopic acti...

see more →

Guidelines  4 results

ACR Appropriateness Criteria® Crohn Disease-Child.
https://doi.org/10.1016/j.jacr.2022.02.020
Journal of the American College of Radiology : JACR; , Moore MM et. al.

May 14th, 2022 - Crohn disease is an inflammatory condition of the gastrointestinal tract with episodes of exacerbation and remission occurring in children, adolescents, and adults. Crohn disease diagnosis and treatment depend upon a combination of clinical, labor...

ACR Appropriateness Criteria® Crohn Disease.
https://doi.org/10.1016/j.jacr.2020.01.030
Journal of the American College of Radiology : JACR; , Kim DH et. al.

May 7th, 2020 - Three common clinical scenarios involving use of imaging in Crohn disease are covered. These include the initial evaluation of Crohn disease when the diagnosis has not been previously established, the evaluation for anticipated exacerbation of kno...

European Society of Paediatric Radiology abdominal imaging task force: statement on ima...
https://doi.org/10.1007/s00247-019-04375-8
Pediatric Radiology; Watson TA, Petit P et. al.

Mar 28th, 2019 - Very early onset inflammatory bowel disease (VEO-IBD) is defined as disease presenting before the age of 6. These children require a tailored imaging approach because conventional imaging studies can be difficult to perform at such a young age. Un...

Surgical Management of Crohn Disease in Children: Guidelines From the Paediatric IBD Po...
https://doi.org/10.1097/MPG.0000000000001562
Journal of Pediatric Gastroenterology and Nutrition; Amil-Dias J, Kolacek S et. al.

Mar 8th, 2017 - The incidence of Crohn disease (CD) has been increasing and surgery needs to be contemplated in a substantial number of cases. The relevant advent of biological treatment has changed but not eliminated the need for surgery in many patients. Despit...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  63 results

Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease
https://clinicaltrials.gov/ct2/show/NCT03712826

Sep 30th, 2022 - Crohn disease is an inflammatory chronic disease of the bowel the complex physiopathology of which brings in immunological, genetic and environmental factors. At present, the appeal to biotherapics anti-TNFa (infliximab and adalimumab) or anti-IL-...

Observational Investigation of the CDED in a Real World IBD Clinic
https://clinicaltrials.gov/ct2/show/NCT05554445

Sep 26th, 2022 - This is a prospective observational study that will follow a cohort of CD patients who are prescribed the Crohn disease exclusion diet (CDED) during their routine clinical dietary therapy at the IBD clinic of the TLVMC. The CD exclusion diet (CDED...

Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
https://clinicaltrials.gov/ct2/show/NCT04508088

Aug 1st, 2022 - Less than optimal bone health has been seen in children that have inflammatory bowel disease (IBD), including Crohn disease (CD). This can present as low bone density or altered bone structure, weakening the bones and increasing fragility and frac...

Ganglioside and IBD
https://clinicaltrials.gov/ct2/show/NCT04782544

Jul 27th, 2022 - Context. Inflammatory bowel disease (IBD) is a chronic and debilitating disorder. Novel treatment strategies aimed to resolve intestinal inflammation and induce disease remission are necessary. Dietary gangliosides are safe for consumption, bioava...

Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease
https://clinicaltrials.gov/ct2/show/NCT03983837

Jul 7th, 2022 - Chronic granulomatous disease (CGD) is a rare genetic immune disorder that results in recurrent and severe infections, and inflammatory dysregulation. For almost 50% of patients with CGD, this inflammation causes severe inflammatory bowel disease ...

see more →

News  199 results

Vedolizumab-Induced Acne Fulminans: An Uncommon and Severe Adverse Effect
https://www.mdedge.com/dermatology/article/258465/acne/vedolizumab-induced-acne-fulminans-uncommon-and-severe-adverse
Kaitlin Blankenship, MD, Laura Burns, MD et. al.

Oct 6th, 2022 - To the Editor: Vedolizumab is an innovative monoclonal antibody targeted against the α4β7 integrin that is approved for treatment of moderate to severe ulcerative colitis and Crohn disease refractory to standard treatment. 1 Vedolizumab is thought.

FDA Drug Approvals, Gastroenterology — 2022 Midyear Review
https://www.medscape.com/viewarticle/978841

Aug 24th, 2022 - Voquezna Triple Pak ( vonoprazan/amoxicillin/clarithromycin) Voquezna Dual Pak (vonoprazan/amoxicillin) Vonoprazan is a first-in-class potassium-competitive acid blocker (PCAB) for treatment of H pylori in combination with clarithromycin and/or am...

Clinical Practice Guidelines for Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula (ASCRS, 2022)
https://www.medscape.com/viewarticle/978286

Aug 8th, 2022 - Clinical practice guidelines on the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula from the American Society of Colon and Rectal Surgeons (ASCRS) were published in August 2022 in Diseases of the Colon & Rectum.[1] For pa...

Lower abdominal pain and dehydration
https://www.mdedge.com/uc-crohn-disease-challenge-center/article/256726/uc-crohn-disease/lower-abdominal-pain-and

Aug 1st, 2022 - The diagnosis in this patient is ulcerative colitis (UC) on the basis of physical examination, laboratory values, and endoscopy. However, this patient has the most extensive form, pancolitis, which means that inflammation and damage extend the ent.

Peristomal Pyoderma Gangrenosum at an Ileostomy Site
https://www.mdedge.com/dermatology/article/256571/rare-diseases/peristomal-pyoderma-gangrenosum-ileostomy-site
Anisha Guda, MD, Ted Rosen, MD

Jul 28th, 2022 - To the Editor: Peristomal pyoderma gangrenosum (PPG) is a rare entity first described in 1984. 1 Lesions usually begin as pustules that coalesce into an erythematous skin ulceration that contains purulent material.

see more →